AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05454384 — intervention group
Intervention type: OTHER
Intervention: Medical Record Examination
Description: The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
Study NCT00688233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seifi's Functional
Description: Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
Study NCT01550705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
Study NCT01520142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26528398
Description: In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
Study NCT01520142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
Study NCT01757912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cuff pressure
Description: The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
Study NCT03936465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
Study NCT03936465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986378
Description: BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
Study NCT00962364 — intervention group
Intervention type: BIOLOGICAL
Intervention: autologous bone marrow-derived cells
Description: autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
Study NCT02493010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arousal-based biofeedback system
Study NCT03136341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abobotulinum toxin A
Description: Dosing will be determined at each study visit based upon muscles involved
Study NCT03136341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be determined at each study visit based upon muscles involved
Study NCT04558775 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: no intervention
Study NCT00880581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: 18 mg injection
Study NCT00880581 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiotherapy
Description: 2 gray (2 Gy) on each of Days 1 and 2
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 monotherapy
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pac-CB
Description: CB-839 in combination with standard dose paclitaxel
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBE
Description: CB-839 in combination with standard dose everolimus
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Erl
Description: CB-839 in combination with standard dose erlotnib
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CB-839 in combination with standard dose docetaxel
Study NCT02071862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Cabo
Description: CB-839 in combination with standard dose cabozantinib
Study NCT02809105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: Oral administration once daily
Study NCT02809105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily
Study NCT01202370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-t-butyldimethylsilyl-10-hydroxycamptothecin
Description: IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
Study NCT03544931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement
Study NCT03544931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Instrumentation
Description: Instrumentation of the root surface in order to achieve debridement
Study NCT03544931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMD Application
Description: Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
Study NCT01601327 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Testosterone enanthate (Sustanon 250 mg)
Description: Twenty-eight patients were treated with testosterone enanthate (TE),
Study NCT01601327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone enanthate (Sustanon 250 mg)
Description: Twenty-eight patients were treated with testosterone enanthate (TE),
Study NCT01601327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)
Description: twenty-five patients were treated with human chorionic gonadotropin (hCG)
Study NCT01601327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosteron gel (Testojel 50 mg)
Description: Twenty-four patients were treated with testosterone gel (TG).
Study NCT03820219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena™ system
Description: The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
Study NCT03820219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard sterile wound dressing
Description: Standard wound care involves the application of an occlusive dressing in the operating room.
Study NCT04653337 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
Study NCT04653337 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
Study NCT04653337 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)
Description: Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
Study NCT03465501 — intervention group
Intervention type: RADIATION
Intervention: Brachytherapy
Description: Brachytherapy
Study NCT01185223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valganciclovir
Description: Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
Study NCT01185223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: 2x5mg/kg/d intravenous ganciclovir
Study NCT01661933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus
Description: Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
Study NCT01661933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus
Description: After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
Study NCT04234295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat Tissue Biopsy
Description: If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
Study NCT04234295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Tissue Biopsy
Description: If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
Study NCT03775122 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TAES
Description: TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
Study NCT03775122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAES
Description: TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
Study NCT01619644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
Study NCT01619644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with an oral dosage of 30 mg/kg/jour
Study NCT00562289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: during the follow up
Study NCT00562289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivitamins K or rivaroxaban or dabigatran or apixaban
Description: during the follow up
Study NCT00562289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devices for PFO closure
Description: endovascular treatment no longer than 21 days after the random.
Study NCT01952119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secure message reminder
Description: Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
Study NCT02957058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCAR technique
Description: Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
Study NCT01993589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers during curattage
Study NCT01993589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparison of pain relievers
Study NCT01764789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01764789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Patients will participate in a quality life assessment.
Study NCT01764789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Participate in multi-component biobehavioral intervention
Study NCT01764789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Participate in multi-component biobehavioral intervention
Study NCT01764789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
Study NCT01764789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in multi-component biobehavioral intervention
Study NCT02971436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake On + Pressure Support A
Description: FPH Device with SensAwake On + Pressure Support A
Study NCT02971436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake Off + Pressure Support A
Description: FPH Device with SensAwake Off + Pressure Support A
Study NCT02971436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake On + Pressure Support B
Description: FPH Device with SensAwake On + Pressure Support B
Study NCT02971436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FPH Device with SensAwake Off + Pressure Support B
Description: FPH Device with SensAwake Off + Pressure Support B
Study NCT01698658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound tomography
Description: Undergo ultrasound tomography using SoftVue
Study NCT01698658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI of the breast
Study NCT03459313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active group
Description: For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
Study NCT04403802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voxx Human Performance Technology Socks
Description: Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming.
Study NCT01202383 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Household-based water treatment with placebo tablets
Description: Study participants will be supplied with tablets and encouraged to use them for treating their water daily
Study NCT00749671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index monitoring
Description: The monitoring of the EEG signal is designed to determine if the sedation is adequate.
Study NCT00749671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramsey Sedation Scale
Description: The determination of the degree of sedation is accomplished using an established sedation scale.
Study NCT02827799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
Study NCT02827799 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Heart Failure Self-Management Education
Description: This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
Study NCT04186884 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04186884 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03282799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant
Description: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
Study NCT03282799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etonogestrel implant
Description: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
Study NCT03501888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: 18 sessions of individual treatment, no manual.
Study NCT03501888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: 18 sessions of group treatment, manual based.
Study NCT04438369 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Cathether based Erector Spinae Plane Block for postoperative pain management.
Study NCT04438369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Cathether based Erector Spinae Plane Block for postoperative pain management.
Study NCT04403802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Socks
Description: Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming.
Study NCT04363385 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological test
Description: Blood sample
Study NCT01322438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) + rifampin
Description: Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Oral
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: IV infusion
Study NCT05498896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion
Study NCT02307110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cross-sectional observation
Description: cross-sectional opthalmic examination
Study NCT01333085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01333085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT01333085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel